Healthcare Intelligence

The global healthcare ecosystem faces a catastrophic human capital deficit and crushing administrative bloat, necessitating a fundamental paradigm shift from passive automation to fully autonomous Agentic AI architectures.

The FDA has authorized 1,451 cumulative AI/ML-enabled medical devices as of end-2025 — 295 in 2025 alone, a record high. AlphaFold 3 delivers 50% greater accuracy than traditional methods for protein-molecule interaction prediction. AI is compressing early-stage drug discovery from 2.5–4 years to 12–18 months. This dossier maps the clinical intelligence revolution and its implications for healthcare systems, pharmaceutical R&D, and investment.

No AI-discovered drug has yet received FDA approval — but 2025 was the inflection year. Insilico Medicine's Rentosertib (ISM001-055) became the first end-to-end AI-discovered drug to complete Phase IIa with demonstrated efficacy, for idiopathic pulmonary fibrosis. AlphaFold 3 (May 2024) improved protein-molecule interaction predictions by ~50% over prior methods. The traditional drug discovery timeline of 10–15 years and $2.6 billion average cost is the benchmark AI must beat. This dossier maps the pipeline, the companies, and the scientific infrastructure of AI-driven drug discovery.

In 2023, López-Otín and colleagues updated the canonical Hallmarks of Aging framework from 9 to 12 hallmarks, adding disabled macroautophagy, chronic inflammation ('inflammaging'), and dysbiosis. Rapamycin — an mTOR inhibitor — remains the most robust life-extension compound across diverse model organisms. The TAME trial (Targeting Aging with Metformin) is the first clinical trial explicitly targeting the aging process rather than any individual disease. Altos Labs (founded 2021, ~$3 billion committed) is the largest private longevity science investment in history. This dossier maps the science and the capital converging on human healthspan extension.

~19% of all FDA-approved medications contain pharmacogenomic information in their labeling. Adverse drug reactions cost the US healthcare system an estimated $30.1 billion annually. The European PREPARE trial demonstrated PGx-guided therapy reduces serious side effects by ~30%. Up to 75% of pharmacogenomically-associated adverse reactions are linked to variants in just three genes: CYP2C19, CYP2D6, and SLCO1B1. The pharmacogenomics market ranges from $3.46B to $19.59B (2025 estimates). This dossier maps the convergence of genomics, AI, and clinical practice.